Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Duster in ashes and dust

<< Previous

Bullboard Posts

Next >>

Post by HarveyTwofaceon Feb 16, 2021 1:12pm

258 Views

Post# 32574608

Duster in ashes and dust

This goes to our favourite Duster: I have to admit something to you - I am long and strong holder, so stopped counting the money I've made on ATE so far, it even gets boring. But what isn't boring is how you, Duster, manage to screw up when to buy ATE and keep the cheap shares instead of trying to short them. You're the funniest guy I 've read about.

<< Previous

Bullboard Posts

Next >>

Barrick Gold employees detained in Mali amid ongoing dispute